Cardiovascular Drugs and Therapy

, Volume 28, Issue 1, pp 61–71 | Cite as

Can Antihypertensive Medication Interfere with the Vicious Cycle Between Hypertension and Vascular Calcification?

  • Maria I. Pikilidou
  • Maria P. Yavropoulou
  • Angelo Scuteri
REVIEW ARTICLE

Abstract

Vascular calcification is a phenomenon of disturbed calcium deposition, as part of the calcium that is supposed to be deposited to our bones, is lodged to our vessels. There are two forms of vascular calcification, each with a distinct anatomical distribution and clinical relevance, namely the intimal and medial calcification. Studies have demonstrated that hypertension may cause vascular calcification but also that both types of calcification, especially medial, promote arterial rigidity and hence hypertension. Implications of this two-way road are largely unknown as there is no consensus yet on their exact clinical value. However, several antihypertensive medications seem to be able to interfere with the cycle of high blood pressure and vascular calcium deposits. The present review summarizes the up-to-date data regarding the effect of antihypertensive medication on vascular calcification.

Keywords

Vascular calcification Antihypertensive medication Angiotensin converting enzyme inhibitors Angiotensin receptor blockers Calcium channel blockers 

References

  1. 1.
    Speer MY, Yang HY, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104:733–41.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Drueke TB. Arterial intima and media calcification: distinct entities with different pathogenesis or all the same? Clin J Am Soc Nephrol. 2008;3:1583–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50–e103.PubMedCrossRefGoogle Scholar
  4. 4.
    Rumberger JA, Brundage BH, Rader DJ, Kondos G. Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc. 1999;74:243–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Raff GL, Abidov A, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. J Cardiovasc Comput Tomogr. 2009;3:122–36.PubMedCrossRefGoogle Scholar
  6. 6.
    Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz. 2001;26:245–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovasc Imaging. 2010;3:1229–36.PubMedCrossRefGoogle Scholar
  8. 8.
    Grayburn PA. Interpreting the coronary-artery calcium score. N Engl J Med. 2012;366:294–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Cheng VY, Lepor NE, Madyoon H, et al. Presence and severity of noncalcified coronary plaque on 64-slice computed tomographic coronary angiography in patients with zero and low coronary artery calcium. Am J Cardiol. 2007;99:1183–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Hausleiter J, Meyer T, Hadamitzky M, et al. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol. 2006;48:312–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Shanahan CM. Inflammation ushers in calcification: a cycle of damage and protection? Circulation. 2007;116:2782–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Karwowski W, Naumnik B, Szczepanski M, Mysliwiec M. The mechanism of vascular calcification—a systematic review. Med Sci Monit. 2012;18:RA1–RA11.PubMedCrossRefGoogle Scholar
  13. 13.
    Rattazzi M, Bertacco E, Puato M, Faggin E, Pauletto P. Hypertension and vascular calcification: a vicious cycle? J Hypertens. 2012;30:1885–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Najjar SS, Scuteri A, Shetty V, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2008;51:1377–83.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Motro M, Shemesh J. Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension. 2001;37:1410–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Essalihi R, Zandvliet ML, Moreau S, et al. Distinct effects of amlodipine treatment on vascular elastocalcinosis and stiffness in a rat model of isolated systolic hypertension. J Hypertens. 2007;25:1879–86.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66:2293–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen NX, Kircelli F, O’Neill KD, Chen X, Moe SM. Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells. Kidney Int. 2010;77:436–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Trion A, Schutte-Bart C, Bax WH, Jukema JW, van der Laarse A. Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination. Mol Cell Biochem. 2008;308:25–33.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Shimizu T, Tanaka T, Iso T, Kawai-Kowase K, Kurabayashi M. Azelnidipine inhibits MSX2-dependent osteogenic differentiation and matrix mineralization of vascular smooth muscle cells. Int Heart J. 2012;53:331–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis. 2012;6:81–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Bruining N, de Winter S, Roelandt JR, et al. Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. Coron Artery Dis. 2009;20:409–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Maahs DM, Snell-Bergeon JK, Kinney GL, et al. ACE-I/ARB treatment in type 1 diabetes patients with albuminuria is associated with lower odds of progression of coronary artery calcification. J Diabetes Complicat. 2007;21:273–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Ng K, Hildreth CM, Avolio AP, Phillips JK. Angiotensin-converting enzyme inhibitor limits pulse-wave velocity and aortic calcification in a rat model of cystic renal disease. Am J Physiol Renal Physiol. 2011;301:F959–66.PubMedCrossRefGoogle Scholar
  25. 25.
    Ng K, Butlin M, Avolio AP. Persistent effect of early, brief angiotensin-converting enzyme inhibition on segmental pressure dependency of aortic stiffness in spontaneously hypertensive rats. J Hypertens. 2012;30:1782–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Armstrong ZB, Boughner DR, Drangova M, Rogers KA. Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model. Cardiovasc Res. 2011;90:165–70.PubMedCrossRefGoogle Scholar
  27. 27.
    Arishiro K, Hoshiga M, Negoro N, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol. 2007;49:1482–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Rahman M, Kim SJ, Kim JS, et al. Myocardial calcification and hypertension following chronic renal failure and ameliorative effects of furosemide and captopril. Cardiology. 2010;116:194–205.PubMedCrossRefGoogle Scholar
  29. 29.
    Tokumoto M, Mizobuchi M, Finch JL, et al. Blockage of the renin-angiotensin system attenuates mortality but not vascular calcification in uremic rats: sevelamer carbonate prevents vascular calcification. Am J Nephrol. 2009;29:582–91.PubMedCrossRefGoogle Scholar
  30. 30.
    Lang F, Ritz E, Voelkl J, Alesutan I. Vascular calcification–is aldosterone a culprit? Nephrol Dial Transplant. 2013;28:1080–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Voelkl J, Alesutan I, Leibrock CB, et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest. 2013;123:812–22.PubMedCentralPubMedGoogle Scholar
  32. 32.
    Wu SY, Yu YR, Cai Y, et al. Endogenous aldosterone is involved in vascular calcification in rat. Exp Biol Med (Maywood). 2012;237:31–7.CrossRefGoogle Scholar
  33. 33.
    Byon CH, Javed A, Dai Q, et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008;283:15319–27.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang M, Zhou SH, Zhao SP, et al. Irbesartan attenuates Ang II-induced BMP-2 expression in human umbilical vein endothelial cells. Vasc Med. 2008;13:239–45.PubMedCrossRefGoogle Scholar
  35. 35.
    Jia G, Stormont RM, Gangahar DM, Agrawal DK. Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification. Am J Physiol Heart Circ Physiol. 2012;303:H523–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Jimenez E, Perez DLB, Urso L, et al. Angiotensin II induces MMP 2 activity via FAK/JNK pathway in human endothelial cells. Biochem Biophys Res Commun. 2009;380:769–74.PubMedCrossRefGoogle Scholar
  37. 37.
    Wang M, Takagi G, Asai K, et al. Aging increases aortic MMP-2 activity and angiotensin II in nonhuman primates. Hypertension. 2003;41:1308–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Jiang L, Zhang J, Monticone RE et al. Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis. Hypertension. 2012.Google Scholar
  39. 39.
    Tziakas DN, Chalikias GK, Stakos DA, et al. Effect of angiotensin-converting enzyme insertion/deletion genotype on collagen type I synthesis and degradation in patients with atrial fibrillation and arterial hypertension. Expert Opin Pharmacother. 2007;8:2225–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Carvajal G, Rodriguez-Vita J, Rodrigues-Diez R, et al. Angiotensin II activates the Smad pathway during epithelial mesenchymal transdifferentiation. Kidney Int. 2008;74:585–95.PubMedCrossRefGoogle Scholar
  41. 41.
    Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, et al. Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 2005;111:2509–17.PubMedCrossRefGoogle Scholar
  42. 42.
    Ruperez M, Lorenzo O, Blanco-Colio LM, et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation. 2003;108:1499–505.PubMedCrossRefGoogle Scholar
  43. 43.
    Albaladejo P, Bouaziz H, Duriez M, et al. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension. 1994;23:74–82.PubMedCrossRefGoogle Scholar
  44. 44.
    Benetos A, Levy BI, Lacolley P, et al. Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 1997;17:3196–201.PubMedCrossRefGoogle Scholar
  45. 45.
    Lacolley P, Safar ME, Lucet B, et al. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Pfohl M, Athanasiadis A, Koch M, et al. Insertion/deletion polymorphism of the angiotensin i-converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998;31:987–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Lange LA, Lange EM, Bielak LF, et al. Autosomal genome-wide scan for coronary artery calcification loci in sibships at high risk for hypertension. Arterioscler Thromb Vasc Biol. 2002;22:418–23.PubMedCrossRefGoogle Scholar
  48. 48.
    Turner ST, Peyser PA, Kardia SL, et al. Genomic loci with pleiotropic effects on coronary artery calcification. Atherosclerosis. 2006;185:340–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Oei HH, Sayed-Tabatabaei FA, Hofman A, et al. The association between angiotensin-converting enzyme gene polymorphism and coronary calcification. The Rotterdam coronary calcification study. Atherosclerosis. 2005;182:169–73.PubMedCrossRefGoogle Scholar
  50. 50.
    Mohammadpour AH, Shamsara J, Nazemi S, et al. Evaluation of RANKL/OPG serum concentration ratio as a new biomarker for coronary artery calcification: a pilot study. Thrombosis. 2012;2012:306263.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 1991;83:469–75.PubMedCrossRefGoogle Scholar
  52. 52.
    Kobayashi N, Mori Y, Mita S, et al. Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats. Eur J Pharmacol. 2001;422:149–57.PubMedCrossRefGoogle Scholar
  53. 53.
    Burnier M, Forni V. Endothelin receptor antagonists: a place in the management of essential hypertension? Nephrol Dial Transplant. 2012;27:865–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Dao HH, Essalihi R, Graillon JF, et al. Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. J Hypertens. 2002;20:1597–606.PubMedCrossRefGoogle Scholar
  55. 55.
    Rabkin SW. Endothelin but not angiotensin II may mediate hypertension-induced coronary vascular calcification in chronic kidney disease. Int J Nephrol. 2011;2011:516237.PubMedCentralPubMedGoogle Scholar
  56. 56.
    Essalihi R, Dao HH, Gilbert LA, et al. Regression of medial elastocalcinosis in rat aorta: a new vascular function for carbonic anhydrase. Circulation. 2005;112:1628–35.PubMedCrossRefGoogle Scholar
  57. 57.
    Hatzistavri LS, Sarafidis PA, Georgianos PI, et al. Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. Am J Hypertens. 2009;22:1070–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Ishimura E, Okuno S, Kitatani K, et al. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol. 2007;68:222–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Schwille PO, Schmiedl A, Schwille R, et al. Media calcification, low erythrocyte magnesium, altered plasma magnesium, and calcium homeostasis following grafting of the thoracic aorta to the infrarenal aorta in the rat–differential preventive effects of long-term oral magnesium supplementation alone and in combination with alkali. Biomed Pharmacother. 2003;57:88–97.PubMedCrossRefGoogle Scholar
  60. 60.
    Kircelli F, Peter ME, Sevinc OE, et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant. 2012;27:514–21.PubMedCrossRefGoogle Scholar
  61. 61.
    Montezano AC, Zimmerman D, Yusuf H, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010;56:453–62.PubMedCrossRefGoogle Scholar
  62. 62.
    Smajilovic S, Hansen JL, Christoffersen TE, et al. Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun. 2006;348:1215–23.PubMedCrossRefGoogle Scholar
  63. 63.
    Ivanovski O, Nikolov IG, Joki N, et al. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE−/−) mice. Atherosclerosis. 2009;205:55–62.PubMedCrossRefGoogle Scholar
  64. 64.
    Massy Z, Drueke T. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012;5 Suppl 1:i52–61.CrossRefGoogle Scholar
  65. 65.
    Budoff MJ, Takasu J, Flores FR, et al. Inhibiting progression of coronary calcification using aged garlic extract in patients receiving statin therapy: a preliminary study. Prev Med. 2004;39:985–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Budoff M. Aged garlic extract retards progression of coronary artery calcification. J Nutr. 2006;136:741S–4S.PubMedGoogle Scholar
  67. 67.
    Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998;104:14S–8S.PubMedCrossRefGoogle Scholar
  68. 68.
    Blumenthal HT, Lansing AI, Wheeler PA. Calcification of the media of the human aorta and its relation to intimal arteriosclerosis. Ageing and Disease. Am J Pathol. 1944;20:665–87.PubMedGoogle Scholar
  69. 69.
    Shemesh J, Motro M, Morag-Koren N, et al. Coronary artery calcification predicts long-term mortality in hypertensive adults. Am J Hypertens. 2011;24:681–6.PubMedCrossRefGoogle Scholar
  70. 70.
    Kim BJ, Choi SY, Lee SH, et al. Advanced coronary artery calcification is associated with ischemic stroke. Cerebrovasc Dis. 2010;30:93–100.PubMedCrossRefGoogle Scholar
  71. 71.
    Kalra SS, Shanahan CM. Vascular calcification and hypertension: cause and effect. Ann Med. 2012;44 Suppl 1:S85–92.PubMedCrossRefGoogle Scholar
  72. 72.
    Jensky NE, Criqui MH, Wright MC, et al. Blood pressure and vascular calcification. Hypertension. 2010;55:990–7.PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005;96:717–22.PubMedCrossRefGoogle Scholar
  74. 74.
    Nakamura S, Ishibashi-Ueda H, Niizuma S, et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol. 2009;4:1892–900.PubMedCrossRefGoogle Scholar
  75. 75.
    Ehara S, Kobayashi Y, Yoshiyama M, et al. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation. 2004;110:3424–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95.PubMedCrossRefGoogle Scholar
  77. 77.
    Wang JG, Staessen J. Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials. J Clin Hypertens (Greenwich). 2003;5:66–75.CrossRefGoogle Scholar
  78. 78.
    Henein MY, Owen A. Statins moderate coronary stenoses but not coronary calcification: results from meta-analyses. Int J Cardiol. 2011;153:31–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Maria I. Pikilidou
    • 1
  • Maria P. Yavropoulou
    • 2
  • Angelo Scuteri
    • 3
  1. 1.Hypertension Excellence Center, 1st Department of Internal MedicineAHEPA University HospitalThessalonikiGreece
  2. 2.Division of Endocrinology and Metabolism, 1st Department of Internal MedicineAHEPA University HospitalThessalonikiGreece
  3. 3.Hospital San Raffaele Pisana IRCCSRomeItaly

Personalised recommendations